Stewart takes responsibility for maximising the value of Amarin’s lead product, AMR101, a new drug currently in Phase 3 clinical trials for the treatment of high triglycerides. The company has also completed enrolment to its Phase 3 Marine trial earlier than expected, with results now due early next year.
Stewart has more than 30 years of experience in the pharmaceutical industry, including five as ceo of CollaGenex Pharmaceuticals. He also worked for the ASTA Medica Group, where for 10 years he managed several business units in the US and internationally. He began his career in sales and marketing for Winthrop Laboratories, in the UK, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.
Declan Doogan, who has been the company’s interim ceo, will continue to support Amarin as chief medical officer for the majority of his time.
Amarin names Colin Stewart as president and ceo
Has been in the pharmaceutical industry for more than 30 years
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
Cloud labelling and serialisation: the new frontline of traceability in drug delivery
As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence